L.V.A.M. Beex

REDUCED MORBIDITY FROM SKELETAL METASTASES IN BREAST CANCER PATIENTS DURING LONG-TERM BISPHOSPHONATE (APD) TREATMENT

A.Th. van Holten-Verzantvoort, O. L. M. Bijvoet, J. Hermans et al. · The Lancet · 1987 · 203 citations

Medicine, Oncology, Surgery +10

Palliative pamidronate treatment in patients with bone metastases from breast cancer.

A.Th. van Holten-Verzantvoort, Hidde M. Kroon, O. L. M. Bijvoet et al. · Journal of Clinical Oncology · 1993 · 197 citations

Medicine, Oncology, Pharmacology +17

Heterozygosity for a point mutation in an invariant splice donor site of dihydropyrimidine dehydrogenase and severe 5-fluorouracil related toxicity

André B. P. Kuilenburg, P. Vreken, L.V.A.M. Beex et al. · European Journal of Cancer · 1997 · 111 citations · Full text

Life Sciences, Genetics, Molecular Genetics +15

EORTC 10968: a phase I clinical and pharmacokinetic study of polyethylene glycol liposomal doxorubicin (Caelyx®, Doxil®) at a 6-week interval in patients with metastatic breast cancer

Anne Hamilton, Laura Biganzoli, Robert E. Coleman et al. · Annals of Oncology · 2002 · 106 citations

Pharmacy, Clinical Pharmacokinetics, Pharmacokinetics +17

CA 125 half-life in ovarian cancer: a multivariate survival analysis

C.A. Yedema, Peter Kenemans, Feja J. Voorhorst et al. · British Journal of Cancer · 1993 · 56 citations · Full text

Medicine, Gynecology, Oncology +10